OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 23:55 UTC. Every row links to its source record.

APC APC regulator of Wnt signaling pathway

ENSG00000134982 · protein coding · Open Targets profile

Tumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)- induced cell migration. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Associates with both microtubules and actin filaments, components of the cytoskeleton (PubMed:17293347). Plays a role in mediating the organization of F- actin into ordered bundles (PubMed:17293347). Functions downstream of Rho GTPases and DIAPH1 to selectively stabilize microtubules (By similarity). Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. It is required for the localization of MACF1 to the cell membrane and this localization of MACF1 is critical for its function in microtubule stabilization. {ECO:0000250|UniProtKB:Q61315, ECO:0000269|PubMed:10947987, ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, ECO:0000269|PubMed:19151759, ECO:0000269|PubMed:19893577, ECO:0000269|PubMed:20937854}.

In 14 of 15 cancers, the evidence for APC comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751familial adenomatous polyposis 1familial adenomatous polyposis 1familial adenomatous polyposis 1: somatic 0.84familial adenomatous polyposis 1: germline 0.96classic familial adenomatous polyposisclassic familial adenomatous polyposisclassic familial adenomatous polyposis: germline 0.89colorectal cancercolorectal cancercolorectal cancer: germline 0.91gastric adenocarcinoma and proximal pol…gastric adenocarcinoma and proximal polyposis of the stomachgastric adenocarcinoma and proximal polyposis of the stomach: germline 0.86colon carcinomacolon carcinomacolon carcinoma: somatic 0.53colon carcinoma: germline 0.89colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.86colonic neoplasmcolonic neoplasmcolonic neoplasm: somatic 0.61colonic neoplasm: germline 0.88hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.53hepatocellular carcinoma: germline 0.93desmoid tumordesmoid tumordesmoid tumor: germline 0.70gastric cancergastric cancergastric cancer: somatic 0.68gastric cancer: germline 0.93classic or attenuated familial adenomat…classic or attenuated familial adenomatous polyposisclassic or attenuated familial adenomatous polyposis: germline 0.93Gardner syndromeGardner syndromeGardner syndrome: germline 0.85rectal neoplasmrectal neoplasmrectal neoplasm: somatic 0.46rectal neoplasm: germline 0.92attenuated familial adenomatous polypos…attenuated familial adenomatous polyposisattenuated familial adenomatous polyposis: germline 0.81adenomatous colon polypadenomatous colon polypadenomatous colon polyp: germline 0.79

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand, High-Quality Ligand
Antibody
UniProt loc high conf, GO CC high conf, Human Protein Atlas loc
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.2915300130844116 (upper bound 0.35468998551368713). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of APC's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of APC's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.